243 related articles for article (PubMed ID: 23614561)
1. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment.
Bacchetti T; Campanati A; Ferretti G; Simonetti O; Liberati G; Offidani AM
Br J Dermatol; 2013 May; 168(5):984-9. PubMed ID: 23614561
[TBL] [Abstract][Full Text] [Related]
2. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1.
Ferretti G; Bacchetti T; Campanati A; Simonetti O; Liberati G; Offidani A
Br J Dermatol; 2012 Jan; 166(1):204-7. PubMed ID: 21790517
[TBL] [Abstract][Full Text] [Related]
3. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
Kanelleas A; Liapi C; Katoulis A; Stavropoulos P; Avgerinou G; Georgala S; Economopoulos T; Stavrianeas NG; Katsambas A
Clin Exp Dermatol; 2011 Dec; 36(8):845-50. PubMed ID: 21790728
[TBL] [Abstract][Full Text] [Related]
4. Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis.
Asefi M; Vaisi-Raygani A; Bahrehmand F; Kiani A; Rahimi Z; Nomani H; Ebrahimi A; Tavilani H; Pourmotabbed T
Br J Dermatol; 2012 Dec; 167(6):1279-86. PubMed ID: 22835076
[TBL] [Abstract][Full Text] [Related]
5. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
6. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study.
Lestre S; Diamantino F; Veloso L; Fidalgo A; Ferreira A
Eur J Dermatol; 2011; 21(6):916-20. PubMed ID: 21983007
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
[TBL] [Abstract][Full Text] [Related]
8. HDL-paraoxonase and membrane lipid peroxidation: a comparison between healthy and obese subjects.
Ferretti G; Bacchetti T; Masciangelo S; Bicchiega V
Obesity (Silver Spring); 2010 Jun; 18(6):1079-84. PubMed ID: 19834469
[TBL] [Abstract][Full Text] [Related]
9. Etanercept improves lipid profile and oxidative stress measures in patients with juvenile idiopathic arthritis.
De Sanctis S; Marcovecchio ML; Gaspari S; Del Torto M; Mohn A; Chiarelli F; Breda L
J Rheumatol; 2013 Jun; 40(6):943-8. PubMed ID: 23547210
[TBL] [Abstract][Full Text] [Related]
10. Treatment of erythrodermic psoriasis with etanercept.
Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of food supplement to improve metabolic syndrome parameters in patients affected by moderate to severe psoriasis during anti-TNFα treatment.
Skroza N; Proietti I; Bernardini N; La Viola G; Nicolucci F; Pampena R; Tolino E; Zuber S; Mancini MT; Soccodato V; Balduzzi V; Potenza C
G Ital Dermatol Venereol; 2013 Dec; 148(6):661-5. PubMed ID: 24442048
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
13. Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.
Ryan C; Kelleher J; Fagan MF; Rogers S; Collins P; Barker JN; Allen M; Hagan R; Renfro L; Kirby B
Clin Exp Dermatol; 2014 Jun; 39(4):519-24. PubMed ID: 24758522
[TBL] [Abstract][Full Text] [Related]
14. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.
van Eijk IC; de Vries MK; Levels JH; Peters MJ; Huizer EE; Dijkmans BA; van der Horst-Bruinsma IE; Hazenberg BP; van de Stadt RJ; Wolbink GJ; Nurmohamed MT
Arthritis Rheum; 2009 May; 60(5):1324-30. PubMed ID: 19404933
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of BuChE non-UU phenotype and paraoxonase (PON1) 55 M allele on the risk of systemic lupus erythematosus: influence on lipid and lipoprotein metabolism and oxidative stress, preliminary report.
Bahrehmand F; Vaisi-Raygani A; Rahimi Z; Ahmadi R; Kiani A; Tavilani H; Vaisi-Raygani H; Pourmotabbed T
Lupus; 2014 Mar; 23(3):263-72. PubMed ID: 24399815
[TBL] [Abstract][Full Text] [Related]
16. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
17. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis.
Campanati A; Orciani M; Gorbi S; Regoli F; Di Primio R; Offidani A
Br J Dermatol; 2012 Jul; 167(1):68-76. PubMed ID: 22356229
[TBL] [Abstract][Full Text] [Related]
18. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
[TBL] [Abstract][Full Text] [Related]
19. Etanercept for psoriasis: two case reports.
Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
[TBL] [Abstract][Full Text] [Related]
20. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
Koc E; Tunca M; Akgul EO; Akar A; Kurt Y; Kurumlu Z; Erbil K; Kilic S
J Dermatol; 2009 Apr; 36(4):191-6. PubMed ID: 19348656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
